Abstract
Purpose: Liver transplantation (LT) has gained ground as a treatment for cholangiocarcinoma. LT has achieved an established role as curative treatment for unresectable hilar cholangiocarcinoma (hCCA), and there are emerging data supporting its use in select patients with intrahepatic cholangiocarcinoma (iCCA). This review explores the current frontiers and future directions of LT for CCA. Recent Findings: Results of retrospective studies support randomized trials of LT for resectable hCCA. Select patients with iCCA who have small tumors or favorable disease biology, as demonstrated by response to neoadjuvant therapy, have long-term survival after LT. Discoveries in the biology of iCCA show patients with FGFR and other genetic abnormalities have improved outcomes and may benefit from targeted therapies. Summary: The outcomes of LT for CCA support its increased utilization. Policies should be considered to increase accessibility of donor organs for patients with iCCA.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 21-27 |
| Number of pages | 7 |
| Journal | Current Transplantation Reports |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2021 |
Keywords
- Cholangiocarcinoma
- Liver transplantation
- Mayo protocol
- Neoadjuvant therapy
ASJC Scopus subject areas
- Surgery
- Immunology
- Hepatology
- Nephrology
- Transplantation